HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.

AbstractCONTEXT:
Acquired generalized lipodystrophy (AGL) is associated with leptin deficiency as a result of adipose tissue loss and hypertriglyceridemia, insulin resistance, and hepatic steatosis. It may coexist with other autoimmune diseases such as Hashimoto's thyroiditis, rheumatoid arthritis, hemolytic anemia, and chronic active hepatitis. Metreleptin therapy has been shown to improve metabolic abnormalities in lipodystrophy, but the effect on AGL patients with active autoimmune disease is unknown.
CASE DESCRIPTION:
We report 3 cases of pediatric patients with AGL and distinct active autoimmune diseases who were treated with metreleptin over a period of 4-6 years. Case 1 is a 9-year-old girl with active juvenile dermatomyositis, who was successfully treated with leptin with no worsening of her dermatomoysitis. Case 2 is a 16-year-old female with Graves' disease, who could discontinue all her antidiabetic medication completely with improved triglyceride levels. Case 3 is an 11-year-old boy with active autoimmune hepatitis and chronic urticaria, whose hyperphagia has resolved and his liver enzymes and hepatosplenomegaly have improved.
CONCLUSION:
Metreleptin therapy is of considerable clinical benefit to reduce insulin resistance and hypertriglyceridemia and did not appear to alter the clinical course of autoimmune disease nor clinical efficacy of immunosuppressive treatments. Our observations suggest that risk or presence of autoimmune disease should not lead to withholding of metreleptin treatment from patients with AGL, but should prompt close clinical follow up in light of cautionary preclinical data.
AuthorsJasmin Lebastchi, Nevin Ajluni, Adam Neidert, Elif A Oral
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 100 Issue 11 Pg. 3967-70 (Nov 2015) ISSN: 1945-7197 [Electronic] United States
PMID26390101 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Leptin
  • metreleptin
Topics
  • Adolescent
  • Autoimmune Diseases (complications, physiopathology)
  • Child
  • Compassionate Use Trials
  • Dermatomyositis (complications, physiopathology)
  • Female
  • Graves Disease (complications, physiopathology)
  • Hepatitis, Autoimmune (complications, physiopathology)
  • Humans
  • Hypoglycemic Agents (adverse effects, therapeutic use)
  • Hypolipidemic Agents (adverse effects, therapeutic use)
  • Leptin (adverse effects, analogs & derivatives, therapeutic use)
  • Lipodystrophy (complications, drug therapy, immunology)
  • Male
  • Severity of Illness Index
  • Treatment Outcome
  • Urticaria (complications, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: